



Bayer AG
Communications
51368 Leverkusen
Germany
Tel. +49 214 30-1
media.bayer.com

News Release

Not intended for U.S. and UK Media

Bayer to highlight latest research on its advancing Oncology portfolio at the AACR20 Virtual Annual Meeting II

- Focus on Targeted Thorium Conjugate (TTC) platform, the company's proprietary targeted alpha therapies program
 - Synergistic effects of investigational PSMA-TTC in combination with androgen receptor inhibitor darolutamide in preclinical prostate cancer
-

Abstracts: 6286 / 21; 5353 / 12; 5355 / 14; 2257 / 10; 1807 / 7; 2907 / 24; 677 / 1; 1776 / 5; 6318 / 1

Berlin, June 17, 2020 – Bayer will present latest research on its advancing Oncology portfolio at the upcoming American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II, taking place from June 22-24, 2020. Highlight presentations will feature preclinical data across the company's targeted alpha therapies program and introduce a novel antibody-drug conjugate (ADC) payload class technology for cancer therapy. Information on the registration as well as the virtual scientific program can be found [here](#).

With the Targeted Thorium Conjugate (TTC) platform, Bayer is advancing an emerging class of novel targeted alpha therapies that combines tumor targeting molecules such as antibodies with the alpha emitter thorium-227. Two presentations will feature preclinical data on thorium (227Th) anetumab corixetan, a mesothelin-targeting TTC currently in Phase 1 clinical development for the treatment of mesothelin-positive tumors such as mesothelioma, ovarian or pancreatic cancer. Another presentation highlights the synergistic anti-cancer effects of a PSMA (prostate-specific membrane antigen)-targeting TTC in combination with darolutamide in preclinical prostate cancer models. Darolutamide (Nubeqa™), which is jointly developed by Bayer and Orion Corporation, is an oral androgen receptor inhibitor indicated for the treatment of men with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease. Additional research presented from Bayer's targeted alpha therapy

program evaluates the effects of radium-223 dichloride (Xofigo™), prednisone and abiraterone acetate on bone in a preclinical model for metastatic castration-resistant prostate cancer (mCRPC).

At the virtual meeting, Bayer will also present on the development of a new payload class for antibody-drug conjugates (ADC) based on nicotinamide phosphoribosyl transferase (NAMPT) inhibition. Inhibition of intracellular NAMPT may represent a differentiated ADC approach independent from cell proliferation, which means not only highly proliferative but also slowly growing tumors and resting antigen-positive tumor cells may be targeted. Preclinical data on anti-tumor activity of NAMPT inhibitor-based ADCs in different models of hematologic and solid tumor indications will be presented. Another presentation in the area of ADCs will cover preclinical data on anetumab ravtansine, a mesothelin-targeting ADC, which look into the ADC's acquired resistance in malignant pleural mesothelioma.

Bayer presentations at the AACR20 Virtual Annual Meeting II are listed below and will be available online beginning June 22, 2020 at 9:00 AM ET (2:45 PM CET):

- ***PSMA-targeted thorium conjugate and darolutamide combination show synergistic anti-tumor activity and reduced expression of DNA damage repair genes in prostate cancer models***
 - Virtual Poster Session: PO.ET09.01 – Novel Radiotherapeutic Technologies and Mechanisms
 - Abstract: 5353 / 12

- ***MSLN-targeted thorium-227 conjugate demonstrates increased antitumor activity in combination with bevacizumab and regorafenib***
 - Virtual Poster Session: PO.ET09.01 – Novel Radiotherapeutic Technologies and Mechanisms
 - Abstract: 5355 / 14

- ***Targeted thorium-227 conjugates demonstrate synergistic activity in combination with PD-L1 inhibitors***
 - Virtual Poster Session: PO.IM02.13 – Immune Mechanisms Invoked by Therapies 2
 - Abstract: 2257 / 10

- *The effects of prednisone, abiraterone acetate and **radium-223 dichloride** on bone in the intratibial LNCaP prostate cancer model*
 - Virtual Poster Session: PO.ET09.02 – Identifying and Modulating Mechanisms of Radiosensitization
 - Abstract: 6286 / 21

- *Anti-tumor activity of a novel structural class of **NAMPT inhibitor**-based ADCs in models of hematologic and solid tumor indications*
 - Virtual Poster Session: PO.ET07.02 – Intracellular Pathways as Drug Targets
 - Abstract: 1807 / 7

- *Identification and optimization of a novel **NAMPT inhibitor**-based ADC payload class for cancer therapy*
 - Virtual Poster Session: PO.ET01.05 – Antibody Drug Conjugates
 - Abstract: 2907 / 24

- *Effective depletion of M2 macrophages by **CD206-NAMPT-ADCs***
 - Virtual Poster Session: PO.ET01.03 – Targeting the Tumor Microenvironment
 - Abstract: 677 / 1

- *Acquired resistance in a malignant pleural mesothelioma preclinical model after treatment with **anetumab ravtansine***
 - Virtual Poster Session: PO.ET03.08 – Mechanisms of Sensitivity and Resistance to Targeted Therapy 3
 - Abstract: 6318 / 1

Acknowledgements: The antibody moiety used in PSMA-TTC is licensed from PSMA Development Company LLC.

About Bayer's Oncology Research Platforms

Bayer focuses its research activities on first-in-class innovations across the following scientific platforms: Oncogenic Signaling, Targeted Alpha Therapies, and Immuno-Oncology. In the field of Oncogenic Signaling the company is developing small molecules and other modalities to target crucial pathways of intracellular tumor signaling that are responsible for the development and survival of cancer in well-defined patient populations

identified using selection biomarker. In regard to Targeted Alpha Therapies drug candidates are being developed using the company's proprietary Thorium-227 platform for delivering high-energy alpha-radiation via different targeting molecules such as antibodies to tumor cells. In Immuno-Oncology Bayer is developing next-generation treatments that intervene at different levels of the cancer immunity cycle specifically addressing patients not responding to immune checkpoint inhibitors.

About Oncology at Bayer

Bayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments. The oncology franchise at Bayer now expands to six marketed products and several other assets in various stages of clinical development. Together, these products reflect the company's approach to research, which prioritizes targets and pathways with the potential to impact the way that cancer is treated.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to www.bayer.com.

Contact:

Dr. Julia Schulze, phone +49 30 468-193636

Email: julia.schulze@bayer.com

Find more information at www.pharma.bayer.com

Our online press service is just a click away: media.bayer.com

Follow us on Facebook: <http://www.facebook.com/pharma.bayer>

Follow us on Twitter: [@BayerPharma](https://twitter.com/BayerPharma)

jds (2020-0153E)

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.